Woodlands, Texas-based biopharmaceutical company Opexa Therapeutics, Inc. will present its most recent clinical results on the immune profile of patients with neuromyelitis optic (NMO) during the 67th American Academy of Neurology (AAN) Annual Meeting, which is taking place in Washington DC. The company is focused on the development of personalized immunotherapies to treat autoimmune disorders, such as NMO and multiple sclerosis (MS).
Opexa is going to host the “Immune profiling of NMO patients receiving B-cell depleting therapy” presentation on two different panels on April 23rd. The company will announce the most recent data from its ongoing research designed to understand the characterization of the cellular immune profile of NMO patients administered with B-cell depleting treatment when compared to those of healthy participants.
The results have demonstrated that regardless of the treatment with B-cell depleting therapy, there was a verified and persistent inflammation, similar to the presence of activated T-cells. Opexa is developing preclinical studies within a NMO program, while it expects an Investigational New Drug application for its drug candidate OPX-212.
The company is seeking to provide an effective treatment for the rare autoimmune disease NMO, which affects immune system cells and antibodies, attacking astrocytes and provoking secondary demyelination of neurons in the optic nerves and spinal cord. Since the condition, for which there is currently no cure or approved treatment, affects between 4,000 and 8,000 patients in the U.S., the U.S. Food and Drug Administration (FDA) has granted it an orphan disease designation.